TY - JOUR
T1 - Reduced Risk of Lymphedema With Intensity-modulated Radiation Therapy Compared With 3-dimensional Conformal Radiation Therapy in Patients With Cervical Cancer Who Received Postoperative Pelvic Radiation Therapy
AU - Uezono, Haruka
AU - Tsujino, Kayoko
AU - Miyazaki, Shuichiro
AU - Marudai, Mitsuru
AU - Bessyo, Ryosuke
AU - Takabayashi, Hatamei
AU - Yamaguchi, Satoshi
AU - Ota, Yosuke
N1 - Publisher Copyright:
© 2023 Wolters Kluwer Health, Inc. All rights reserved.
PY - 2023/8/1
Y1 - 2023/8/1
N2 - Objectives: To compare the long-term adverse events of intensity-modulated radiation therapy (IMRT) with those of 3-dimensional conformal radiation therapy (3D-CRT) in patients with intermediate-risk and high-risk uterine cervical cancer who underwent postoperative pelvic radiation therapy (PORT). Methods: We reviewed the medical records of 177 patients with cervical cancer who underwent radical surgery and PORT. IMRT and 3D-CRT were administered to 93 and 84 patients, respectively. Follow-up and toxicity assessments were then carried out. Results: The median follow-up period was 63 months (range: 3 to 177). There was a significant difference in the follow-up period between the IMRT and 3D-CRT cohorts (median: 59 vs. 112 mo, P<0.0001). The crude incidences of acute grade 2+ and grade 3+ gastrointestinal toxicities were significantly lower with IMRT than with 3D-CRT (22.6% vs. 48.1%, P=0.002, and 3.2% vs. 11.1%, P=0.04, respectively). The Kaplan-Meier estimates of late toxicities revealed that IMRT significantly reduced grade 2+ genitourinary (GU) toxicity and lower-extremity lymphedema ([LEL] requiring intervention) compared with 3D-CRT ([6.8% vs. 15.2% at 5-year, P=0.048] and [3.1% vs. 14.6% at 5-year, P=0.0029], respectively). IMRT was the only significant predictor of reducing LEL risk. Conclusions: The risks of acute gastrointestinal toxicity, late GU toxicity, and LEL from PORT for cervical cancer were reduced by IMRT. Lower inguinal doses may have contributed to a lower risk of developing LEL, which should be validated in future studies.
AB - Objectives: To compare the long-term adverse events of intensity-modulated radiation therapy (IMRT) with those of 3-dimensional conformal radiation therapy (3D-CRT) in patients with intermediate-risk and high-risk uterine cervical cancer who underwent postoperative pelvic radiation therapy (PORT). Methods: We reviewed the medical records of 177 patients with cervical cancer who underwent radical surgery and PORT. IMRT and 3D-CRT were administered to 93 and 84 patients, respectively. Follow-up and toxicity assessments were then carried out. Results: The median follow-up period was 63 months (range: 3 to 177). There was a significant difference in the follow-up period between the IMRT and 3D-CRT cohorts (median: 59 vs. 112 mo, P<0.0001). The crude incidences of acute grade 2+ and grade 3+ gastrointestinal toxicities were significantly lower with IMRT than with 3D-CRT (22.6% vs. 48.1%, P=0.002, and 3.2% vs. 11.1%, P=0.04, respectively). The Kaplan-Meier estimates of late toxicities revealed that IMRT significantly reduced grade 2+ genitourinary (GU) toxicity and lower-extremity lymphedema ([LEL] requiring intervention) compared with 3D-CRT ([6.8% vs. 15.2% at 5-year, P=0.048] and [3.1% vs. 14.6% at 5-year, P=0.0029], respectively). IMRT was the only significant predictor of reducing LEL risk. Conclusions: The risks of acute gastrointestinal toxicity, late GU toxicity, and LEL from PORT for cervical cancer were reduced by IMRT. Lower inguinal doses may have contributed to a lower risk of developing LEL, which should be validated in future studies.
KW - adverse event
KW - cervical cancer
KW - intensity-modulated radiation therapy
KW - lymphedema
KW - postoperative radiation therapy
UR - https://www.scopus.com/pages/publications/85165748810
UR - https://www.scopus.com/pages/publications/85165748810#tab=citedBy
U2 - 10.1097/COC.0000000000001018
DO - 10.1097/COC.0000000000001018
M3 - Article
C2 - 37231540
AN - SCOPUS:85165748810
SN - 0277-3732
VL - 46
SP - 346
EP - 352
JO - American Journal of Clinical Oncology: Cancer Clinical Trials
JF - American Journal of Clinical Oncology: Cancer Clinical Trials
IS - 8
ER -